Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Gross Profit (2022 - 2025)

Historic Gross Profit for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $103.2 million.

  • Immunocore Holdings' Gross Profit rose 2929.82% to $103.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.9 million, marking a year-over-year increase of 2831.52%. This contributed to the annual value of $307.5 million for FY2024, which is 2378.51% up from last year.
  • Immunocore Holdings' Gross Profit amounted to $103.2 million in Q3 2025, which was up 2929.82% from $96.9 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Gross Profit registered a high of $103.2 million during Q3 2025, and its lowest value of $38.9 million during Q2 2022.
  • In the last 4 years, Immunocore Holdings' Gross Profit had a median value of $70.3 million in 2024 and averaged $73.5 million.
  • Over the last 5 years, Immunocore Holdings' Gross Profit had its largest YoY gain of 5280.61% in 2023, and its largest YoY loss of 421.71% in 2023.
  • Immunocore Holdings' Gross Profit (Quarter) stood at $67.1 million in 2022, then increased by 4.22% to $70.0 million in 2023, then grew by 19.67% to $83.7 million in 2024, then rose by 23.24% to $103.2 million in 2025.
  • Its Gross Profit stands at $103.2 million for Q3 2025, versus $96.9 million for Q2 2025 and $93.0 million for Q1 2025.